Our Experience and Literature Update Regarding Concomitant Radiotherapy with CDK4/6 Inhibitors and Hormonal Therapy in Metastatic Breast Cancer by Laura-Florentina Rebegea, Dorel Firescu, Oana-Gabriela Trifanescu, Roxana-Andreea Rahnea-Nita, Liviu Bilteanu, Mihaela Dumitru, Florentina Lacatus, Gabriela Rahnea-Nita

Subjects: “…CDK4/6 inhibitors…”
Get full text

Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis by Yanrong Kang, Bing Han, Yongmei Kong, Shuai Liu, Nan Zhang

Subjects: “…CDK4/6 inhibitors…”
Get full text

Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study by Seda Kahraman, Mutlu Hizal, Burcin Cakan Demirel, Deniz Can Guven, Ozge Gumusay, Basak Oyan Uluc, Ertugrul Bayram, Burcu Gulbagci, Alper Yasar, Sena Ece Davarci, Eda Eylemer Mocan, Omer Acar, Deniz Isik, Esra Aydin, Yusuf Karakas, Melike Ozcelik, Murat Keser, Sadi Kerem Okutur, Onder Eren, Serkan Menekse, Dincer Aydin, Funda Yilmaz, Ozlem Dogan, Gulhan Ozkanli, Hakan Yucel, Veli Sunar, Musa Baris Aykan, Ozlem Ozdemir, Berna Bozkurt Duman, Merve Keskinkilic, Teoman Sakalar, Ali Inal, Muge Karaoglanoglu, Asude Aksoy, Muhammed Muhiddin Er, Nazim Serdar Turhal, Nurhan Onal Kalkan, Mehmet Ali Nahit Sendur

Subjects: “…CDK 4/6 inhibitors…”
Get full text

Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review by Chen Z, Xie P, Chen Q, Ouyang J

Subjects: Get full text

Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors by Zehra Sucuoğlu İşleyen, Harun Muğlu, Zeynep Alaca Topçu, Mehmet Beşiroğlu, Ayşe İrem Yasin, Atakan Topçu, Melih Şimşek, Mesut Şeker, Hacı Mehmet Türk

Subjects: Get full text

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them by L. Foffano, L. Cucciniello, E. Nicolò, I. Migliaccio, C. Noto, C. Reduzzi, L. Malorni, M. Cristofanilli, L. Gerratana, F. Puglisi

Subjects: Get full text

A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer by Jialin Zhang, Xinyu Xu, Yeyue Zhou, Jingyang Su, Jue Wang

Subjects: Get full text

Lesson from a metastatic male breast cancer case: CDK4/6 plus aromatase inhibitors could not exceed tamoxifen by Tala Najdi, Samah Seif, Nahed Damaj, Joseph Kattan

Subjects: Get full text

Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors by Pınar Kubilay Tolunay, Bediz Kurt İnci, Şura Usta, Ali Topkaç, Berkan Karabuğa, Ergin Aydemir, İrem Öner, Büşra Akay Hacan, Öztürk Ateş, Cengiz Karaçin, Ülkü Yalçıntaş Arslan

Subjects: “…CDK4/6 inhibitors…”
Get full text

Ribociclib-Induced Delayed Dermatological Reaction: Case Report of a Rare Adverse Effect and Review of Literature by Bhavika Kothari, Pallavi Parab, Seema Gulia, Sushmita Rath, Sudeep Gupta

Subjects: Get full text

Monitoring concentration and lipid signature of plasma extracellular vesicles from HR+ metastatic breast cancer patients under CDK4/6 inhibitors treatment by Mathilde Richard, Rosalie Moreau, Mikaël Croyal, Laurent Mathiot, Jean‐Sébastien Frénel, Mario Campone, Aurélien Dupont, Julie Gavard, Gwennan André‐Grégoire, Laëtitia Guével

Subjects: Get full text

CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’... by E. V. Artamonova, E. I. Kovalenko, L. V. Bolotina, M. B. Stenina, R. V. Orlova, M. A. Mukhina

Subjects: Get full text

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors by Roberta Scafetta, Marco Donato, Carla Gullotta, Alessandra Guarino, Cristina Fiore, Luisana Sisca, Elena Speziale, Raffaella Troiano, Simone Foderaro, Valentina Ricozzi, Michele Iuliani, Sonia Simonetti, Silvia Cavaliere, Alessio Cortellini, Andrea Botticelli, Simone Scagnoli, Simona Pisegna, Carmen Criscitiello, Rebecca Pedersini, Caterina Sposetti, Elisa Tiberi, Giuliana D'Auria, Matteo Vergati, Marco Mazzotta, Roberta Caputo, Annarita Verrazzo, Maria Grazia Rossino, Federica Domati, Claudia Piombino, Francesca Sofia Di Lisa, Lorena Filomeno, Teresa Arcuri, Federica Puce, Federica Riva, Michela Palleschi, Marianna Sirico, Marta Piras, Luigia Stefania Stucci, Delia De Lisi, Paolo Orsaria, Edy Ippolito, Sara Ramella, Luca Visani, Niccolò Bertini, Ilaria Bonaparte, Stefania Gori, Luigi Rossi, Icro Meattini, Barbara Tagliaferri, Orazio Caffo, Ilaria Portarena, Azzurra Irelli, Elisabetta Cretella, Camillo Porta, Giampaolo Bianchini, Agnese Fabbri, Ugo De Giorgi, Patrizia Vici, Angela Toss, Ornella Garrone, Michelino De Laurentiis, Federica Villa, Rossana Berardi, Mauro Minelli, Claudio Vernieri, Giuseppe Curigliano, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini, Francesco Pantano

Subjects: Get full text

Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system by Wensheng Liu, Wensheng Liu, Feifei Gao, Feifei Gao, Xue Song, Hao Chen, Hao Chen, Youjun She, Youjun She, Jiyong Liu, Jiyong Liu, Qiong Du, Qiong Du

Subjects: “…CDK4/6 inhibitors…”
Get full text

Survival outcomes in trial defined high-risk hormone receptor-positive/human epidermal growth factor receptor II-negative early breast cancer: impact of adjuvant chemotherapy by Ta-Chung Chao, Deanna Gracia, Chan-Heng Ho, Hao-Yang Chen, Chi-Cheng Huang, Ling-Ming Tseng

Subjects: Get full text

How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy? by Peeter Karihtala

Subjects: Get full text

The Effect of Proton Pump Inhibitors on Metastatic Breast Cancer in Patients Treated with CDK4/6i by Mohamed Khalifa, Amrallah Mohammed, Yara Mohamed, Isra Mahgoub, Mohamed Awadallah, Basant Elshafaay, Amira Hanna, Ahmed Obaya, Yaser Arafat

Subjects: Get full text

Drug Treatment Direction Based on the Molecular Mechanism of Breast Cancer Brain Metastasis by Yumin Zhang, Haotian Shang, Jiaxuan Zhang, Yizhi Jiang, Jiahao Li, Huihua Xiong, Tengfei Chao

Subjects: Get full text

Gene expression analysis in circulating tumour cells to determine resistance to CDK4/6 inhibitors plus endocrine therapy in HR + /HER2- metastatic breast cancer patients by Miriam González-Conde, Celso Yáñez, Carmen Abuín, Corinna Keup, Ramón Lago-Lestón, Maribel Aybar, Lucía Pedrouzo, Patricia Palacios, Teresa Curiel, Juan Cueva, Carmela Rodríguez, Marta Carmona, Alexandra Cortegoso, Tomás García-Caballero, Laura Muinelo-Romay, Sabine Kasimir-Bauer, Rafael López-López, Clotilde Costa

Subjects: Get full text

Integrating single-cell regulatory atlas and multi-omics data for differential treatment response and multimodal predictive modeling in CDK 4/6 inhibitor-treated breast cancer by Li Yan, Li Yan, Sijie Chen, Sijie Chen, Ran Ran, Ran Ran, Shidi Zhao, Shidi Zhao, Jing Huang, Jing Huang, Jin Yang, Jin Yang, Jin Yang, Jin Yang

Subjects: Get full text